Pharmaceutical

ArsenalBio secures $325m to develop cell therapy programmes

ArsenalBio has secured $325m in a Series C financing round to propel its programmable cell therapy programmes through clinical development.

Sep 6, 2024 - 04:00
ArsenalBio secures $325m to develop cell therapy programmes
ArsenalBio has secured $325m in a Series C financing round to propel its programmable cell therapy programmes through clinical development.
Read the original article

Tags:

Previous Article

UK bans xylazine and 21 other substances to fight drug abuse

Next Article

Lilly and EVA Pharma to expand baricitinib access in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GLB-001 by GluBio Therapeutics for Relapsed Acute Myelo...

Dec 20, 2023

STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market

STAT+: With new trial data, a blockbuster therapy from ...

Nov 27, 2023

STAT+: In setback, Pfizer abandons one weight loss pill and bets on another

STAT+: In setback, Pfizer abandons one weight loss pill...

Jun 26, 2023